Bristol-Myers Squibb Company vs Novavax, Inc.: SG&A Expense Trends

SG&A Expense Trends: Bristol-Myers Squibb vs. Novavax

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and Novavax, Inc. from 2014 to 2023. Over this period, Bristol-Myers Squibb consistently outspent Novavax, with its SG&A expenses peaking in 2022 at approximately 7.8 billion dollars, a 70% increase from 2014. In contrast, Novavax's expenses, while significantly lower, showed a dramatic rise, especially post-2020, reaching nearly 490 million dollars in 2022, marking a staggering 2,350% increase from 2014. This surge reflects Novavax's aggressive market expansion and strategic investments in response to global health challenges. As the pharmaceutical landscape continues to shift, these financial trends offer a window into the strategic priorities and market positioning of these industry giants.